Impact Of Increasing Men Geriatric Population On The Prostate Cancer Drugs Market: Pivotal Factor Influencing Prostate Cancer Drugs Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Prostate Cancer Drugs Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the market for prostate cancer medications has seen significant expansion. The market, which stood at $18.53 billion in 2024, is anticipated to increase to $19.77 billion in 2025, showcasing a compound annual growth rate (CAGR) of 6.7%. The substantial growth in the historical period is driven by factors such as an ageing population, a rise in diagnoses, advancements in drug research, heightened awareness and education, as well as reimbursement and insurance options.

How Will the Prostate Cancer Drugs Market Size Evolve and Grow by 2029?
In the forthcoming years, the market size for prostate cancer drugs is predicted to experience significant growth. An annual growth rate (CAGR) of 6.2% is expected, projecting a total market size of $25.13 billion by 2029. Several factors contribute to the anticipated growth during this forecast period including increasing cases, emerging markets, favorable government policies, and research and development investments. Key trends predicted for this period encompass precision medicine, immunotherapy and targeted therapies, personalized medicine, clinical trials, drug pipelines, combination therapies, treatments driven by biomarkers, and advancements in telemedicine and remote monitoring.

View the full report here:
https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

What Drivers Are Propelling the Growth of Prostate Cancer Drugs Market Forward?
The surge in the elderly male population significantly propels the prostate cancer drugs market. Prostate cancer frequently occurs in men over 60, making it one of the most common forms of cancer for this age group. The US government organization, Administration For Community Living (ACL), predicts a 21.6% increase in the aged population by 2040. Statistically, prostate cancer impacts men more than it does women. Citing the American Cancer Society, a recognized US organization, prostate cancer is more prevalent in elderly men and non-Hispanic black men, with 6 in 10 diagnoses occurring in men aged 65 or older. Hence, the escalating older male population is a significant growth catalyst for the prostate cancer market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp

Which Emerging Trends Are Transforming the Prostate Cancer Drugs Market in 2025?
Emerging trends in the market point to the increasing use of combination therapy for the treatment of prostate cancer. This is largely attributed to the ineffectiveness of monotherapy in some prostate cancer cases. As a result, more investments are being funneled into combination therapy by firms in the prostate cancer drugs industry. Case in point, Pfizer recently shared the findings of its Phase 3 PROSPER trial on non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) patients. The study reveals that the pairing of XTANDI (enzalutamide) with androgen deprivation therapy (ADT) owes to a 71% reduction in the risk of developing metastasis or death compared to the use of ADT alone. Equally, other combination therapies like merging radiation therapy and ADT for men battling recurrent prostate cancer, and the concurrent use of the chemotherapy drug docetaxel (Taxotere) and ADT are gaining traction in treating prostate cancer.

What Are the Key Segments in the Prostate Cancer Drugs Market?
The prostate cancer drugs market covered in this report is segmented -

1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer
2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy
3) By End User: Hospitals, Clinics, Other End-Users

Subsegments:
1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer
2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2592&type=smp

Who Are the Key Players Shaping the Prostate Cancer Drugs Market's Competitive Landscape?
Major companies operating in the prostate cancer drugs market include Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, F. Hoffmann-La Roche AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., GlaxoSmithKline plc, Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Agios Pharmaceuticals Inc., Exelixis Inc.

What Geographic Markets Are Powering Growth in the Prostate Cancer Drugs Market?
North America was the largest region in the prostate cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2592

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.